One Plus One Wealth Management LLC Has $254,000 Stock Position in AbbVie Inc. (NYSE:ABBV)

One Plus One Wealth Management LLC cut its position in AbbVie Inc. (NYSE:ABBV) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,431 shares of the company’s stock after selling 63 shares during the period. One Plus One Wealth Management LLC’s holdings in AbbVie were worth $254,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Morris Financial Concepts Inc. grew its position in AbbVie by 7.0% in the 4th quarter. Morris Financial Concepts Inc. now owns 2,736 shares of the company’s stock valued at $486,000 after purchasing an additional 179 shares during the period. Hemington Wealth Management increased its position in shares of AbbVie by 6.3% during the fourth quarter. Hemington Wealth Management now owns 2,536 shares of the company’s stock worth $450,000 after acquiring an additional 150 shares in the last quarter. McClarren Financial Advisors Inc. raised its holdings in shares of AbbVie by 8.9% in the 4th quarter. McClarren Financial Advisors Inc. now owns 770 shares of the company’s stock worth $137,000 after acquiring an additional 63 shares during the last quarter. Warren Street Wealth Advisors LLC lifted its position in AbbVie by 49.4% in the 4th quarter. Warren Street Wealth Advisors LLC now owns 3,044 shares of the company’s stock valued at $541,000 after acquiring an additional 1,006 shares in the last quarter. Finally, MFG Wealth Management Inc. acquired a new position in AbbVie during the 4th quarter valued at about $1,684,000. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Up 0.6 %

Shares of AbbVie stock opened at $193.06 on Thursday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The stock has a market capitalization of $341.16 billion, a P/E ratio of 80.44, a P/E/G ratio of 1.53 and a beta of 0.58. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The stock’s 50-day simple moving average is $177.91 and its 200 day simple moving average is $185.86.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same quarter in the previous year, the firm earned $2.79 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on ABBV shares. Bank of America reissued a “neutral” rating and issued a $191.00 price objective on shares of AbbVie in a research note on Tuesday, December 10th. Piper Sandler Companies reissued an “overweight” rating and issued a $220.00 price target on shares of AbbVie in a research report on Tuesday, December 17th. Daiwa America downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 5th. Sanford C. Bernstein initiated coverage on shares of AbbVie in a report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 target price for the company. Finally, Leerink Partnrs upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $208.35.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.25% of the stock is owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.